294 related articles for article (PubMed ID: 25023700)
1. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.
Patel A; Burton DG; Halvorsen K; Balkan W; Reiner T; Perez-Stable C; Cohen A; Munoz A; Giribaldi MG; Singh S; Robbins DJ; Nguyen DM; Rai P
Oncogene; 2015 May; 34(20):2586-96. PubMed ID: 25023700
[TBL] [Abstract][Full Text] [Related]
2. MTH1 expression is required for effective transformation by oncogenic HRAS.
Giribaldi MG; Munoz A; Halvorsen K; Patel A; Rai P
Oncotarget; 2015 May; 6(13):11519-29. PubMed ID: 25893378
[TBL] [Abstract][Full Text] [Related]
3. Human Mut T Homolog 1 (MTH1): a roadblock for the tumor-suppressive effects of oncogenic RAS-induced ROS.
Rai P
Small GTPases; 2012; 3(2):120-5. PubMed ID: 22790201
[TBL] [Abstract][Full Text] [Related]
4. The high expression of MTH1 and NUDT5 promotes tumor metastasis and indicates a poor prognosis in patients with non-small-cell lung cancer.
Li DN; Yang CC; Li J; Ou Yang QG; Zeng LT; Fan GQ; Liu TH; Tian XY; Wang JJ; Zhang H; Dai DP; Cui J; Cai JP
Biochim Biophys Acta Mol Cell Res; 2021 Jan; 1868(1):118895. PubMed ID: 33096144
[TBL] [Abstract][Full Text] [Related]
5. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.
Huber KV; Salah E; Radic B; Gridling M; Elkins JM; Stukalov A; Jemth AS; Göktürk C; Sanjiv K; Strömberg K; Pham T; Berglund UW; Colinge J; Bennett KL; Loizou JI; Helleday T; Knapp S; Superti-Furga G
Nature; 2014 Apr; 508(7495):222-7. PubMed ID: 24695225
[TBL] [Abstract][Full Text] [Related]
6. Association of MTH1 expression with the tumor malignant potential and poor prognosis in patients with resected lung cancer.
Fujishita T; Okamoto T; Akamine T; Takamori S; Takada K; Katsura M; Toyokawa G; Shoji F; Shimokawa M; Oda Y; Nakabeppu Y; Maehara Y
Lung Cancer; 2017 Jul; 109():52-57. PubMed ID: 28577950
[TBL] [Abstract][Full Text] [Related]
7. Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence.
Rai P; Young JJ; Burton DG; Giribaldi MG; Onder TT; Weinberg RA
Oncogene; 2011 Mar; 30(12):1489-96. PubMed ID: 21076467
[TBL] [Abstract][Full Text] [Related]
8. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
10. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1.
Dai X; Guo G; Zou P; Cui R; Chen W; Chen X; Yin C; He W; Vinothkumar R; Yang F; Zhang X; Liang G
J Exp Clin Cancer Res; 2017 Sep; 36(1):120. PubMed ID: 28882182
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
12. Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue.
McPherson LA; Troccoli CI; Ji D; Bowles AE; Gardiner ML; Mohsen MG; Nagathihalli NS; Nguyen DM; Robbins DJ; Merchant NB; Kool ET; Rai P; Ford JM
DNA Repair (Amst); 2019 Nov; 83():102644. PubMed ID: 31311767
[TBL] [Abstract][Full Text] [Related]
13. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
[TBL] [Abstract][Full Text] [Related]
14. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.
Kumar MS; Hancock DC; Molina-Arcas M; Steckel M; East P; Diefenbacher M; Armenteros-Monterroso E; Lassailly F; Matthews N; Nye E; Stamp G; Behrens A; Downward J
Cell; 2012 Apr; 149(3):642-55. PubMed ID: 22541434
[TBL] [Abstract][Full Text] [Related]
15. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.
Vicent S; Chen R; Sayles LC; Lin C; Walker RG; Gillespie AK; Subramanian A; Hinkle G; Yang X; Saif S; Root DE; Huff V; Hahn WC; Sweet-Cordero EA
J Clin Invest; 2010 Nov; 120(11):3940-52. PubMed ID: 20972333
[TBL] [Abstract][Full Text] [Related]
16. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
[TBL] [Abstract][Full Text] [Related]
17. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
[TBL] [Abstract][Full Text] [Related]
18. Potent and specific MTH1 inhibitors targeting gastric cancer.
Zhou W; Ma L; Yang J; Qiao H; Li L; Guo Q; Ma J; Zhao L; Wang J; Jiang G; Wan X; Adam Goscinski M; Ding L; Zheng Y; Li W; Liu H; Suo Z; Zhao W
Cell Death Dis; 2019 Jun; 10(6):434. PubMed ID: 31164636
[TBL] [Abstract][Full Text] [Related]
19. MutT Homolog1 has multifaceted role in glioma and is under the apparent orchestration by Hypoxia Inducible factor1 alpha.
Bhavya B; Easwer HV; Vilanilam GC; Anand CR; Sreelakshmi K; Urulangodi M; Rajalakshmi P; Neena I; Padmakrishnan CJ; Menon GR; Krishnakumar K; Deepti AN; Gopala S
Life Sci; 2021 Jan; 264():118673. PubMed ID: 33130078
[TBL] [Abstract][Full Text] [Related]
20. AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.
Das I; Gad H; Bräutigam L; Pudelko L; Tuominen R; Höiom V; Almlöf I; Rajagopal V; Hansson J; Helleday T; Egyházi Brage S; Warpman Berglund U
Cell Death Differ; 2020 Jul; 27(7):2081-2098. PubMed ID: 31919461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
